PODXL and neoplasm: As a first step to determining the proportion of patients that could benefit of a PODO447-based immunotherapy, we evaluated the expression of the PODXL core protein (PODO83 immunoreactivity) and the PODO447-reactive epitope across multiple HGSOC tumors by IHC using tumor samples from the four different HGSOC patient arrays described in Table 1 (different colors Figures 1B, C).